Room For HCV-Focused Start-Ups If The Technology Is Truly Novel
This article was originally published in Start Up
Executive Summary
Hepatitis C has been the focus of some of biopharma’s most expensive deals the past couple years. In the wake of the licensing, IPO, and M&A frenzy, not many new start-ups have emerged, but there are a still a few niches to fill if entrepreneurs can find funding.